The Australian Council of Social Service (ACOSS) has called on the federal government to heed the growing community concern about affordable, accessible universal health care; and to focus on evidence-based solutions to pull back wasteful spending in the health Budget.
"We know that our health system faces increasing costs with an ageing and growing population, but it's certainly not a crisis," said ACOSS CEO Cassandra Goldie, adding: "Savings measures should be selected that will either drive improved health outcomes, or cut real waste in existing spending."
She noted that Australia’s Prime Minister has asked for alternatives to the government's proposals for the Health Budget. “ACOSS welcomes the invitation. Our proposals are grounded in evidence and would improve the effectiveness of government spending in improving health outcomes for the greatest number of people,” Dr Goldie argued.
Urges the government to overhaul industry subsidies
Of particular relevance to the pharmaceutical sector will be the OCOSS call for changes to industry subsidies. Dr Goldie said the group want the government to Overhaul ineffective industry subsidies including in the Pharmaceutical Benefits Scheme (PBS) with an initial saving of almost A$2 billion ($1.64 billion) to reduce the cost of out of patent prescription medicines. Simply introducing single pricing mechanisms, or accelerating these reforms in other ways, can deliver significant further savings. ACOSS has proposed alternatives that would provide a A$1.8 billion dollar saving in this area in the next final year, increasing to A$2 billion in 2016-17.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze